Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its prostate cancer treatment developments and supply chain strength [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from February 21, 2025, to August 28, 2025, with a deadline for lead plaintiff appointments set for January 9, 2026 [2]. - The complaint alleges that Telix overstated its progress in developing and commercializing prostate cancer treatments, leading to materially misleading public statements [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status at no cost [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions, corporate governance litigation, and M&A appraisals, focusing on enhancing investor returns through advocacy [4].
Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TLX